Q-omics provides the consensus-scored NT5C profile across patient tissues and cancer cell-line models. NT5C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NT5C is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NT5C protein abundance shows 29,392 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, KIRC, and BRCA as cancer lineages where NT5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5C survival associations across molecular data types. NT5C RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5C RNA expression–survival associations across cancer types. High NT5C expression shows unfavorable associations in ACC, LIHC, UVM, LGG, SKCM and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NT5C RNA expression.
This table summarizes NT5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NT5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5C shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, HNSC, STAD and ESCA. The KIRC box plot shows higher NT5C RNA expression in tumor versus normal tissue (log2 FC = +0.635, t-test p < 0.001).
This table shows molecular features associated with NT5C in patient tissues and cancer cell lines. In patient samples, NT5C shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
